Peer-reviewed veterinary case report
Recombinant Der f 2 allergy shots for atopic dogs in Hungary
By Fischer, Nina et al.·Published in Veterinary dermatology·2018·Clinic for Small Animal Internal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland.
- Species:
- dog
Plain-English summary
A group of 15 atopic dogs in Switzerland and Hungary, who were suffering from itching and skin problems due to allergies to house dust mites, received a new type of immunotherapy using a recombinant Der f 2 allergen. Over six weeks, the dogs were given weekly injections, and their symptoms were closely monitored. By the end of the treatment, most dogs showed significant improvement, with four dogs having excellent responses and nine others showing good to fair results. This new treatment may work faster than traditional allergy therapies for these dogs.
People also search for: dog itching treatment · house dust mite allergy in dogs · immunotherapy for dog skin problems
Abstract
BACKGROUND: Previously published studies evaluating a recombinant Der f 2-based immunotherapy have demonstrated efficacy in the treatment of dogs experimentally and naturally sensitized to house dust mites (HDM). Der f 2 sensitization is thought to play a minor role in European atopic dogs sensitized to HDM. OBJECTIVE: The study evaluated the short-term efficacy of a recombinant Der f 2 product in the treatment of naturally sensitized atopic dogs in Switzerland and Hungary. ANIMALS: Fifteen atopic dogs with positive test reactions to Dermatophagoides farinae (Df). MATERIAL AND METHODS: Recombinant Der f 2 allergens were injected subcutaneously at increasing doses once weekly for 6 weeks. Canine Atopic Dermatitis Extent and Severity Index (CADESI-04), pruritus Visual Analog Scale (pVAS) and medication scores were assessed at days 0 and 42. Efficacy was recorded as excellent, good, fair or poor, depending on the number of scores decreasing by more than 50%. RESULTS: Mean CADESI, pVAS and medication scores at inclusion were 35, 6 and 15 (SD = 30, 2, 7), respectively. At Day 42 the scores decreased to 8, 3 and 5, respectively (Wilcoxon matched pairs signed rank tests P = 0.0002, 0.002 and 0.001). Four dogs were classified as excellent responders with a reduction of >50% in all three scores. Nine dogs were classified as good (five) or fair (four) responders and scores deteriorated in two dogs. CONCLUSION: These data suggest that recombinant Der f2 allergens may be as effective and show benefit faster than traditional allergen immunotherapy in European dogs sensitized to Df.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29911320/